Navigation Links
Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
Date:6/4/2013

d tumors.
Session Title: General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Presenter: Monica Arnedos , MD, Institut Gustave Roussy, Paris, France

In studying the safety of MM-121 in combination with gemcitabine (Arm A), carboplatin (Arm B),  pemetrexed (Arm C) and cabazitaxel (Arm D) for subjects with advanced cancer, patients were treated in a dose escalation "3+3" design. MM-121 was administered weekly in combination with these cytotoxic agents to assess the safety, tolerability and pharmacokinetics of the antibody. Doses were escalated until the maximum tolerated dose (MTD) was identified and/or the combination was shown to be tolerable at the highest planned doses. Secondary objectives included determining the objective response rate, clinical benefit rate, pharmacokinetics and immunogenicity of MM-121. No MTD was identified for the combination of MM-121 and standard doses of gemcitabine, pemetrexed and cabazitaxel; a MTD of carboplatin (AUC 5) was identified in combination with the recommended dose of MM-121 (40 mg/kg loading, followed by 20 mg/kg weekly maintenance). The two dose limiting toxicities observed in combination with carboplatin were one grade 3-4 prolonged thrombocytopenia and one grade 3 maculopapular rash.

Overall adverse events reported for MM-121 in combination with these cytotoxic agents were similar to adverse events reported for the cytotoxic agents as single agents. Common adverse events included diarrhea, nausea, fatigue and anemia.

The combination of MM-121 and the cytotoxic agents evaluated in this study showed preliminary activity (16% of patients achieved a partial response).

For full details on the study, please view the full poster on our

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
2. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
5. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
6. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
7. Ampio Pharmaceuticals Provides Clinical Updates
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
10. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... consumer research and marketing communication tools are essential ... globally competitive – consequently consumers, desires, preferences, and ... this environment, market research groups across all industries ... marketing communication tools. However, the adoption of new ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... Texas, Oct. 12 Researchers at Texas State University-San ... and anti-retroviral compound with promising results. , Dhiraj Vattem, ... and Reed Richardson, professor in the Department of Agriculture, ... Results were announced at a University press conference. ...
... Oct. 12 RSB Spine, LLC, today announced that the ... reclassification of interbody fusion devices occurred in 2007, the C-Ti ... Drug Administration. With this most recent announcement, the C-Ti ... cleared as an anterior cervical plate as well. , RSB ...
Cached Medicine Technology:Texas State Tests Potential New Cancer-Fighting Weapon 2
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... Doctor’s Office Urgent Care of Paramus, New Jersey has served ... They’ve treated over 40,000 patients while carrying out their mission ... the Paramus area. , For 2015, the practice is ... top-notch board certified physicians: Christine Milosis MD, Sandra Ugras Rey ... will work tirelessly to carry out The Doctor’s Office ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... The Twin Cities DI Day is ... the nation! Over 250 financial professionals come together each ... the industry, get motivated to protect their clients and ... and overcoming the challenges of disability. , On September ... came together to attend The 13th Annual Twin Cities ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... Inc. (Nasdaq: ENDO ), an innovative medical ... technologies for tissue and tumor ablation, today announced that ... with the Securities and Exchange Commission (SEC) in connection ... declared effective by the SEC, the final proxy statement/prospectus ...
... Increased Product DemandBOTHELL, Wash., Jan. 26 BioLife ... developer and marketer of proprietary GMP hypothermic storage ... organs, today announced record revenue for the fourth ... receipt of $1.4 million in funding for operations ...
... children. Obtaining and preserving these valuable cells will create peace-of-mind for ... Gunsaulis, DDS Dentistry for Children, is a pediatric dental practice involved in ... , ... Spokane, WA (PRWEB) January 26, 2009 -- A routine trip ...
... at long-term care facility to quicken admissions process and improve ... ... (PRWEB) January 26, 2009 -- Patient Placement Systems announced today ... Ill., has signed on to use the Web-based Referral Management ...
... Certified Recruitment Firm,Offers Focused Approach to Meet Surge in ER Patient ... ... -- Reacting to market demands, joint commission certified recruitment firm now ... ,"With visits to emergency rooms across the U.S. increasing annually by ...
... ARBOR, Mich. Despite recent government efforts, the medical ... States are not being met, according to data from ... is the substantial growth in those numbers, from approximately ... insurance and children without a regular source of health ...
Cached Medicine News:Health News:Endocare Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Galil Medical 2Health News:Endocare Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Galil Medical 3Health News:Endocare Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Galil Medical 4Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3Health News:Dr. Molly Gunsaulis Offers Parents the Chance to Ensure Their Child's Future Health by Saving Stem Cells from Baby Teeth 2Health News:Fairview Baptist Home Selects PatientPlacement.com to Automate Referrals and Increase Patient and Resident Admissions 2Health News:Fairview Baptist Home Selects PatientPlacement.com to Automate Referrals and Increase Patient and Resident Admissions 3Health News:Jackson & Coker Expands Emergency Medicine Staffing 2Health News:Jackson & Coker Expands Emergency Medicine Staffing 3Health News:Unmet medical needs are most common among vulnerable children 2Health News:Unmet medical needs are most common among vulnerable children 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: